BINEX Co., Ltd. (KOSDAQ:053030)
6,670.00
-90.00 (-1.33%)
Sep 9, 2026, 3:30 PM KST
BINEX Revenue
BINEX had revenue of 37.81B KRW in the quarter ending June 30, 2026, a decrease of -15.09%. This brings the company's revenue in the last twelve months to 157.28B, up 2.68% year-over-year. In the year 2025, BINEX had annual revenue of 168.47B with 29.55% growth.
Revenue (ttm)
157.28B
Revenue Growth
+2.68%
P/S Ratio
1.35
Revenue / Employee
218.45M
Employees
667
Market Cap
212.42B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 168.47B | 38.42B | 29.55% |
| Dec 31, 2024 | 130.05B | -24.77B | -16.00% |
| Dec 31, 2023 | 154.82B | -1.85B | -1.18% |
| Dec 31, 2022 | 156.68B | 22.28B | 16.58% |
| Dec 31, 2021 | 134.40B | 1.42B | 1.07% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| DongKook Pharmaceutical | 979.60B |
| Huons Global | 846.78B |
| PharmaResearch | 603.58B |
| ST Pharm | 386.46B |
| Sam Chun Dang Pharm. | 259.90B |
| Oscotec | 144.18B |
| CG Invites | 30.11B |
| Mezzion Pharma | 8.43B |